Plasma and Cerebrospinal Fluid Pharmacokinetics of Moxifloxacin in a Patient with Tuberculous Meningitis
- 1 June 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (6), 2293-2295
- https://doi.org/10.1128/aac.01637-07
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with TuberculosisClinical Infectious Diseases, 2007
- Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugsRespiratory Medicine, 2006
- Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Long-Term Tolerance and Effectiveness of Moxifloxacin Therapy for Tuberculosis: Preliminary ResultsJournal of Chemotherapy, 2003
- In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosisInternational Journal of Antimicrobial Agents, 2002
- Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli MeningitisAntimicrobial Agents and Chemotherapy, 2001
- Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral AdministrationClinical Pharmacokinetics, 2001
- Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a PenicillinResistant Pneumococcus in RabbitsAntimicrobial Agents and Chemotherapy, 1998